Inhibrx Inc. (NASDAQ:INBX) saw an upside of 5.45% to close Friday at $17.40 after adding $0.9 on the day. The 5-day average trading volume is 467,880 shares of the company’s common stock. It has gained $17.95 in the past week and touched a new high 3 times within the past 5 days. An average of 476,140 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 366,696.
INBX’s 1-month performance is -30.82% or -$7.72 on its low of $15.01 reached on 08/14/23. The company’s shares have touched a 52-week low of $12.60 and high of $34.72, with the stock’s rally to the 52-week high happening on 06/15/23. YTD, INBX has lost -29.38% or -$7.24 and has reached a new high 6 times. However, the current price is down -49.88% from the 52-week high price.
Insider Transactions
INBX stock investors last saw insider trading activity on Mar 01.Eckelman Brendan P. (Chief Scientific Officer) most recently sold 40,000 shares at $24.21 per share on Mar 01. This transaction cost the insider $968,231. Chief Executive Officer, Lappe Mark, sold 60 shares at a price of $25.02 on Feb 28. Then, on Feb 02, Chief Scientific Officer Eckelman Brendan P. sold 11,250 shares at a price of $25.45 per share. This transaction amounted to $286,355.
Valuation Metrics
INBX stock has a beta of 2.74. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1200.89.
Inhibrx Inc.’s quick ratio for the period ended June 29 was 6.50, with the current ratio over the same period at 6.50. The trailing 12-month EBITDA margin is -5798.21%. The firm’s gross profit as reported stood at $131.31 million against revenue of $2.19 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 19.81% to -$47.05 million, while revenue of -$48.92 million was -3.97% off the previous quarter. Analysts expected INBX to announce -$1.03 per share in earnings in its latest quarter, but it posted -$1.08, representing a -4.90% surprise. EBITDA for the quarter stood at more than -$39.83 million. INBX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 237.98 million, with total debt at $208.61 million. Shareholders hold equity totaling $43.67 million.
Let’s look briefly at Inhibrx Inc. (INBX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 39.68% to suggest the stock is trending Neutral, with historical volatility in this time period at 93.02%.
The stock’s 5-day moving average is $16.73, reflecting a +9.09% or $1.45 change from its current price. INBX is currently trading -30.87% above its 20-day SMA, -14.33% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -29.44% and SMA200 by-45.93%.
Stochastic %K and %D was 28.09% and 24.16% and the average true range (ATR) pointed at 1.28. The RSI (14) points at 36.09%, while the 14-day stochastic is at 38.49% with the period’s ATR at 1.31. The stock’s 9-day MACD Oscillator is pointing at 0.36 and -0.96 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Inhibrx Inc. (NASDAQ: INBX), SMBC Nikko launched coverage with an Outperform rating. Analysts offering their rating for INBX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate INBX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 4 have offered a “buy” rating.
What is INBX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $45.00 and a high of $60.00, with their median price target at $50.50. Looking at these predictions, the average price target given by analysts is for Inhibrx Inc. (INBX) stock is $51.50.
